Alnylam Pharmaceuticals Liabilities 2024

Alnylam Pharmaceuticals Aktienanalyse

What does Alnylam Pharmaceuticals do?

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA-based therapeutics for the treatment of severe genetic and other diseases. The company was founded in 2002 by John Maraganore and Phillip Sharp and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Alnylam Pharmaceuticals's Liabilities

Alnylam Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Alnylam Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Alnylam Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Alnylam Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Alnylam Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Alnylam Pharmaceuticals stock

What is the level of liabilities of Alnylam Pharmaceuticals this year?

Alnylam Pharmaceuticals has a debt balance of 4.05 B USD this year.

What were the liabilities of Alnylam Pharmaceuticals compared to the previous year?

The liabilities of Alnylam Pharmaceuticals have increased by 9.34% increased compared to the previous year.

What are the consequences of high debt for investors of Alnylam Pharmaceuticals?

High liabilities can pose a risk for investors of Alnylam Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Alnylam Pharmaceuticals?

Low liabilities mean that Alnylam Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Alnylam Pharmaceuticals affect the company?

An increase in liabilities of Alnylam Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Alnylam Pharmaceuticals affect the company?

A decrease in the liabilities of Alnylam Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Alnylam Pharmaceuticals?

Some factors that can influence the liabilities of Alnylam Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Alnylam Pharmaceuticals so important for investors?

The liabilities of Alnylam Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Alnylam Pharmaceuticals take to modify the liabilities?

To change its liabilities, Alnylam Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Alnylam Pharmaceuticals pay?

Over the past 12 months, Alnylam Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alnylam Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Alnylam Pharmaceuticals?

The current dividend yield of Alnylam Pharmaceuticals is .

When does Alnylam Pharmaceuticals pay dividends?

Alnylam Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Alnylam Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alnylam Pharmaceuticals located?

Alnylam Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alnylam Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alnylam Pharmaceuticals from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Alnylam Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Alnylam Pharmaceuticals in the year 2023?

In the year 2023, Alnylam Pharmaceuticals distributed 0 USD as dividends.

In which currency does Alnylam Pharmaceuticals pay out the dividend?

The dividends of Alnylam Pharmaceuticals are distributed in USD.